Literature DB >> 33941502

COVID-19 vaccine prioritisation for people with cystic fibrosis.

Siobhán B Carr1, Rebecca Cosgriff2, Satenik Harutyunyan1, Peter G Middleton1, Rasa Ruseckaite1, Susannah Ahern1, Géraldine Daneau1, Luiz Vicente R F da Silva Filho1, Anne L Stephenson1, Stephanie Y Cheng1, Joel Melo1, Harriet Corvol1, Pierre-Régis Burgel1, Lutz Nährlich1, Edward McKone1, Carla Colombo1, Marco Salvatore1, Rita Padoan1, Olzhas Abdrakhmanov1, Vincent Gulmans1, Catherine A Byrnes1, Elena Amelina1, Elena Kondratyeva1, Elena Zhekayte1, Nataliya Kashirskaya1, Marco Zampoli1, M Dolores Pastor-Vivero1, Pedro Mondejar-Lopez1, Isabelle de Monestrol1, Andeas Jung1, Elliot McClenaghan1, Keith Brownlee1, Samar Rizvi1, Christopher H Goss1, Alexander Elbert1, Albert Faro1, Hector Gutierrez1, Bruce C Marshall1.   

Abstract

Entities:  

Keywords:  COVID; Coronavirus; Cystic fibrosis; Vaccine

Year:  2021        PMID: 33941502     DOI: 10.1016/j.jcf.2021.03.028

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


× No keyword cloud information.
  1 in total

1.  Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies.

Authors:  Gianfranco Alicandro; Valeria Daccò; Lisa Cariani; Chiara Rosazza; Calogero Sathya Sciarrabba; Federica Ferraro; Chiara Lanfranchi; Paola Medino; Daniela Girelli; Carla Colombo
Journal:  Biomedicines       Date:  2022-08-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.